Skip to content

Study · Randomized controlled trial · n = 350 · 2017

4 results

Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.

Meneilly GS, Roy-Duval C, Alawi H, Dailey G, Bellido D, Trescoli C, Manrique Hurtado H, Guo H, Pilorget V, Perfetti R, Simpson H

Diabetes care10 Feb 2017Cited by 30 (Europe PMC)

PMID28188240 (opens in a new tab)DOI10.2337/dc16-2143 (opens in a new tab)PepBankPUB-28188240
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In nonfrail patients with type 2 diabetes aged ≥70 years, lixisenatide reduced HbA1c more than placebo at week 24.

    In plain wordsLixisenatide reduced long-term blood sugar more than placebo in nonfrail older patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c change at week 24
    Study

    n = 350

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily before breakfast · 24 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.57%
    lixisenatide
    HbA1c decrease
    6.2 mmol/mol
    lixisenatide
    HbA1c change
    0.06%
    placebo
    HbA1c increase
    0.7 mmol/mol
    placebo
    P value
    < 0.0001
    comparison

    Source sentences

    Summary
    HbA1c decreased substantially with lixisenatide (-0.57% [6.2 mmol/mol]) compared with placebo (+0.06% [0.7 mmol/mol]) from baseline to week 24 (P < 0.0001).
    2 context sentences
    Summary · context
    In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks.
    Summary · context
    Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In nonfrail older patients with type 2 diabetes, lixisenatide reduced postprandial glucose more than placebo.

    In plain wordsLixisenatide reduced after-meal blood sugar more than placebo in nonfrail older patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    Decrease2-hour postprandial plasma glucose
    Study

    n = 350

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 μg once daily before breakfast · 24 weeksAs given in this study (human).

    Measurements

    PPG change
    −5.12 mmol/L
    lixisenatide
    PPG change
    −0.07 mmol/L
    placebo
    P value
    < 0.0001
    comparison

    Source sentences

    Summary
    Mean reduction in 2-h PPG was significantly greater with lixisenatide (-5.12 mmol/L) than with placebo (-0.07 mmol/L; P < 0.0001).
    2 context sentences
    Summary · context
    In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks.
    Summary · context
    Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In nonfrail older patients with type 2 diabetes, lixisenatide reduced body weight more than placebo.

    In plain wordsLixisenatide reduced body weight more than placebo in nonfrail older patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBody weight
    Study

    n = 350

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    20 μg once daily before breakfast · 24 weeksAs given in this study (human).

    Measurements

    Body weight change
    −1.47 kg
    lixisenatide
    Body weight change
    −0.16 kg
    placebo
    P value
    < 0.0001
    comparison

    Source sentences

    Summary
    A greater decrease in body weight was observed with lixisenatide (-1.47 kg) versus placebo (-0.16 kg; P < 0.0001).
    2 context sentences
    Summary · context
    In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks.
    Summary · context
    Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded.
  4. 04HumanRandomized controlled trialSafety outcome

    In nonfrail older patients with type 2 diabetes, hypoglycemia was reported more frequently with lixisenatide than placebo.

    In plain wordsLow blood sugar was more frequent with lixisenatide than placebo in nonfrail older patients with type 2 diabetes.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHypoglycemia incidence
    Study

    n = 350

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    20 μg once daily before breakfast · 24 weeksAs given in this study (human).

    Measurements

    Hypoglycemia incidence
    17.6%
    lixisenatide
    Hypoglycemia incidence
    10.3%
    placebo

    Source sentences

    Summary
    Hypoglycemia was reported in 17.6% of patients with lixisenatide versus 10.3% with placebo.
    2 context sentences
    Summary · context
    In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks.
    Summary · context
    Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01798706

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

Sanofin = 350Jun 2013 to Feb 2015

Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 18 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.